Recovery begins upstream.
A compounded CJC-1295 without DAC and ipamorelin prescription organized around upstream signaling, sleep rhythm, and recovery.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
About 10 minutes. No charge unless your clinician approves.
Two upstream signals. Kept short and pulsatile.
Recovery is not only what you do after training. It is also the hormonal environment your body is working inside while the rebuilding happens. CJC-1295 without DAC and ipamorelin are paired around that upstream layer.
This formulation uses CJC-1295 without DAC. Its action is short, measured in minutes rather than days, which keeps growth hormone release pulsatile instead of continuously elevated. It acts through the growth hormone releasing hormone pathway. Ipamorelin approaches the same GH axis through the growth hormone secretagogue receptor, giving the pair two distinct upstream inputs into pituitary GH release.
That combination is what makes the biology interesting. It is not administered growth hormone, and it is not a long-acting DAC product sitting in the background for a week. The formulation is built around brief signaling and the pulsatile physiology of the GH axis.
The recovery chain is sleep rhythm, upstream growth-hormone signaling, then the work of rebuilding. This is not synthetic HGH and it is not a promise about bulking or physique outcomes.
For the recovery question beneath the program.
The Slow-Recovery Athlete
Training and nutrition are already serious, but the space between hard sessions feels more expensive than it used to. You want the endocrine side evaluated rather than assuming more effort is the answer.
The GH-Axis Reader
You understand that stimulating upstream GH signaling is different from administering growth hormone directly. You want that distinction handled precisely, without the mythology around the category.
The Systems Thinker
You are interested in recovery as the interaction between training, sleep, nutrition, and endocrine signaling. A clinician-guided combination makes more sense to you than a research vial and a dosing forum.
Compounded CJC-1295 / Ipamorelin is not an FDA-approved drug product. Whether it is appropriate for you is determined by a licensed provider from your full Assessment.
This might not be the right fit if:
- Active or suspected malignancy, or a history of cancer without oncology clearance
- A history of pituitary disease or pituitary surgery, without clearance from the clinician managing it
- Diabetes, prediabetes, or any medication that lowers blood sugar, without clearance from the clinician managing it
- Competing in a tested sport, unless you have confirmed the position with your governing body
- Pregnancy or breastfeeding
- Known hypersensitivity to any component of the preparation
- Under 18
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
CJC-1295 / Ipamorelin, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- CJC-1295 confirmed without DAC, with short-acting rather than extended-half-life biology
- Ipamorelin paired as a second upstream GH-secretagogue signal
- Your clinician sets the dose and schedule for the individual prescription
- Medical history, endocrine context, medications, and goals reviewed before treatment
- Compounded to the individual prescription by a licensed US pharmacy if approved
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Recovery & Repair.
BPC-157
The peptide everyone asks about, inside real medicine.
Compounded BPC-157 sourced through a licensed US pharmacy and placed inside clinician review, not a research-vendor checkout.
BPC-157 Oral
A capsule that meets the digestive tract directly.
Compounded oral BPC-157 delivered directly into the digestive tract, with a clinician deciding whether capsule or injection fits the case.
Wolverine Stack
Two repair pathways. One prescription.
A compounded BPC-157 and TB-500 prescription pairing BPC-157's tissue-repair signaling with thymosin beta-4 biology in cell movement and wound closure.
Commonly reported
- Injection site reactions
- Headache
- Diarrhea
- Flushing
The honest disclosure here is the size of the evidence base. Almost all published human data on CJC-1295 describes the long-acting DAC version rather than the short-acting molecule in this preparation; the reported effects are from those trials. Ipamorelin has one controlled human trial of any size, given intravenously to patients after bowel surgery, where adverse events were common in both the treated and placebo groups; there is no comparable dataset for subcutaneous use in healthy adults. Because both compounds push growth hormone release, your provider screens for active or recent cancer, asks about pituitary history, and reviews blood sugar and any diabetes medication given the ghrelin receptor involvement. Both compounds are prohibited at all times by the World Anti-Doping Agency, and human safety data for this combination is limited, which is the reason it sits with a clinician rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
No. This combination is not synthetic HGH. It uses two compounded upstream peptides studied for growth-hormone signaling. It is not a bodybuilding shortcut, and body-composition or recovery outcomes are not guaranteed. The clinical question is whether that signaling approach fits the individual case.
They approach the GH axis through different upstream receptor systems. The CJC component acts through GHRH signaling, while ipamorelin is a growth hormone secretagogue acting through the GHS receptor. The pairing is designed around those complementary signals, not around a claim that the combination is proven to improve recovery outcomes.
Neither this compounded combination nor the finished preparation is FDA-approved. CJC-1295 has no current FDA compounding pathway, and ipamorelin acetate appears on FDA Category 2 for 503B outsourcing facilities, a published safety concern that does not bind the 503A pharmacy filling an individual prescription here. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
Here, a licensed provider reviews whether the combination belongs in your care, and a licensed US pharmacy compounds it to your individual prescription. Research-market products do not provide the same prescribing record, pharmacy accountability, or ongoing clinical follow-up.
Any time, before your renewal date. No phone calls required.